Kymera Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kymera Therapeutics, Inc.
Sanofi outlines progress on developing a differentiated R&D pipeline in immunology, including novel ways of addressing COPD, atopic dermatitis and autoimmune disorders.
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.
Korea's SK Group expands its biopharma business via a sizable investment in Roivant's protein degradation platform, through which the partners aim to progress candidates in cancer, immunology and neurology, with the first entering the clinic next year.
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- Kymera Therapeutics, LLC.